Evidence map›Paper›PMID 41609875›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Utilizing nanotechnology to diagnose and treat central nervous system disorders.

Erfan Shahabinejad, Amirreza Shakoeizadeh, Mojgan Noroozi Karimabad, Fatemeh Asadi, Mahdi Heydari, Marzie Salandari-Rabori

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Erfan Shahabinejad *Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. e.shahabinejad@rums.ac.ir.ORCID http://orcid.org/0000-0002-0204-0394
Amirreza Shakoeizadeh *Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Mojgan Noroozi KarimabadMolecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Fatemeh AsadiFaculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Mahdi HeydariSchool of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Marzie Salandari-RaboriSocial Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. msalandari85@yahoo.com.ORCID http://orcid.org/0000-0002-5193-6939

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CNS presents a unique challenge to therapeutic intervention due to its sophisticated organization, the protective blood-brain barrier (BBB), and the low regenerative potential of neural tissue. Over the last few decades, nanotechnology has emerged as a revolutionary technology capable of transforming the diagnosis and treatment of CNS diseases, thereby offering new hope to patients with previously incurable neurodegenerative diseases. This review highlights the therapeutic and diagnostic potential of newer types of nanomaterials-i.e., nanoliposomes (NLs), metallic nanoparticles (MNPs), and carbon nanotubes (CNTs)-which have been found to cross the blood-brain barrier (BBB) and deliver drugs with enhanced specificity and efficacy. Nanoparticle-based therapies have revolutionized drug delivery, gene therapy, in vivo imaging, and molecular profiling for CNS diseases. However, despite such advancements, hurdles remain, particularly in terms of biocompatibility, long-term safety, and site-specific activity within complex biological systems. Herein, we summarize recent advances in the construction of smart nanocarriers and multi-functional platforms for overcoming physiological and pharmacological challenges in CNS therapy. Finally, we emphasize the urgent need for interdisciplinary studies to unlock the full clinical potential of nanotechnology in neurology and answer outstanding questions regarding toxicity, immune responses, and scalability for human application.

Indexed as

Central Nervous System DiseasesDrug Delivery SystemsNanotechnologyAnimalsHumansAlzheimer's diseaseCentral nervous systemNanotechnologyParkinson's disease

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.